Ontology highlight
ABSTRACT: Background
Limited data are available on the economic costs of respiratory syncytial virus (RSV) infections among infants and young children in the United States.Methods
We performed a systematic literature review of 10 key databases to identify studies published between 1 January 2014 and 2 August 2021 that reported RSV-related costs in US children aged 0-59 months. Costs were extracted and a systematic analysis was performed.Results
Seventeen studies were included. Although an RSV hospitalization (RSVH) of an extremely premature infant costs 5.6 times that of a full-term infant ($10 214), full-term infants accounted for 82% of RSVHs and 70% of RSVH costs. Medicaid-insured infants were 91% more likely than commercially insured infants to be hospitalized for RSV treatment in their first year of life. Medicaid financed 61% of infant RSVHs. Paying 32% less per hospitalization than commercial insurance, Medicaid paid 51% of infant RSVH costs. Infants' RSV treatment costs $709.6 million annually, representing $187 per overall birth and $227 per publicly funded birth.Conclusions
Public sources pay for more than half of infants' RSV medical costs, constituting the highest rate of RSVHs and the highest expenditure per birth. Full-term infants are the predominant source of infant RSVHs and costs.
SUBMITTER: Bowser DM
PROVIDER: S-EPMC9377037 | biostudies-literature | 2022 Aug
REPOSITORIES: biostudies-literature
Bowser Diana M DM Rowlands Katharine R KR Hariharan Dhwani D Gervasio Raíssa M RM Buckley Lauren L Halasa-Rappel Yara Y Glaser Elizabeth L EL Nelson Christopher B CB Shepard Donald S DS
The Journal of infectious diseases 20220801 Suppl 2
<h4>Background</h4>Limited data are available on the economic costs of respiratory syncytial virus (RSV) infections among infants and young children in the United States.<h4>Methods</h4>We performed a systematic literature review of 10 key databases to identify studies published between 1 January 2014 and 2 August 2021 that reported RSV-related costs in US children aged 0-59 months. Costs were extracted and a systematic analysis was performed.<h4>Results</h4>Seventeen studies were included. Alth ...[more]